Divalproex Sodium

Divalproex Sodium is used to treat bipolar disorder, epilepsy, absence epilepsy and complex partial epilepsy, per the National Library of Medicine's MED-RT classification. The brand product was first FDA-approved on Mar 10, 1983, and the first generic was approved Jul 29, 2008. FDA's Orange Book lists 59 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $241 million on Divalproex Sodium across 5.2 million claims for 698,000 beneficiaries.

Divalproex Sodium is available as 125 NDCs from 21 manufacturers (119 generic, 6 brand), with NADAC prices from $0.05 to $7.46 per EA — the most expensive product costs about 136× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.